Martin Ho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6688042/publications.pdf

Version: 2024-02-01

16 papers	733 citations	12 h-index	940134 16 g-index
16	16	16	668
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis. Statistics in Biopharmaceutical Research, 2023, 15, 29-42.	0.6	19
2	The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis. Statistics in Biopharmaceutical Research, 2023, 15, 43-56.	0.6	32
3	Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment. Statistics in Biopharmaceutical Research, 2023, 15, 3-13.	0.6	24
4	Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson's Disease. MDM Policy and Practice, 2021, 6, 238146832110213.	0.5	7
5	Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study. MDM Policy and Practice, 2021, 6, 238146832097840.	0.5	12
6	A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. Value in Health, 2016, 19, 746-750.	0.1	106
7	Joint Estimation of Treatment and Placebo Effects in Clinical Trials With Longitudinal Blinding Assessments. Journal of the American Statistical Association, 2016, 111, 538-548.	1.8	4
8	A Causal Model for Joint Evaluation of Placebo and Treatmentâ€Specific Effects in Clinical Trials. Biometrics, 2013, 69, 318-327.	0.8	13
9	Safety and Efficacy of a Calcineurin Inhibitor Avoidance Regimen in Pediatric Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2006, 17, 1735-1745.	3.0	62
10	Racial and Center Differences in Hemodialysis Adequacy in Children Treated at Pediatric Centers: A North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Report. Journal of the American Society of Nephrology: JASN, 2004, 15, 2923-2932.	3.0	22
11	Morbidity and mortality in children with anemia at initiation of dialysis. Pediatric Nephrology, 2003, 18, 1055-1062.	0.9	105
12	Survival of childhood polycystic kidney disease following renal transplantation: The impact of advanced hepatobiliary disease. Pediatric Transplantation, 2003, 7, 364-369.	0.5	68
13	American Pediatric Renal Transplant Cooperative Study (NAPRTCS) is a voluntary collaborative effort comprising over 150 pediatric renal disease treatment centers in the United States, Canada, Mexico and Costa Rica. It is supported by major, unrestricted educational grants from Novartis, AMGEN, and Genentech. Participating NAPRTCS Centers are listed in the most recent NAPRTCS Annual Report	2.6	78
14	[Seikaly M, Ho PL, E. Kidney International, 2003, 63, 744-755. Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. Journal of Pediatrics, 2003, 142, 539-545.	0.9	90
15	Outcome of renal transplantation in adolescents with focal segmental glomerulosclerosis. Pediatric Transplantation, 2002, 6, 488-492.	0.5	60
16	Automated Peritoneal Dialysis Symposium: The Role of APD in the Management of Pediatric Patients: A Report of the North American Pediatric Renal Transplant Cooperative Study. Seminars in Dialysis, 2002, 15, 427-429.	0.7	31